Going green Next Generation Pharmaceutical (Europe)              Collaboration and innovation Next Generation Pharmaceutical (Europe)              Pushing the frontiers of disease prevention Next Generation Pharmaceutical (Europe)              The power of perception Next Generation Pharmaceutical (Europe)              Supply chain optimisation Next Generation Pharmaceutical (Europe)              Translational medicine paradigm: hip or hype? Next Generation Pharmaceutical (US)              The evolution of drug safety Next Generation Pharmaceutical (US)              Investigating cell death resistance in tumor cells Next Generation Pharmaceutical (US)              A culture of engagement and inclusion Next Generation Pharmaceutical (US)              Leading Lilly forward Next Generation Pharmaceutical (US)             

Contributors

John Lechleiter
John Lechleiter
COO, Eli Lilly
Leading Lilly forward

Ken Murtha
Ken Murtha
Regional VP Supply for the Americas, AstraZeneca
The importance of operations

Jill Robinson
Jill Robinson
VP of Global Safety Surveillance, Wyeth Research
The new risk management paradigm

Mary Ellen Turner
Mary Ellen Turner
VP Risk Management, Wyeth Research
The new risk management paradigm

Dr. Andreas Busch
Dr. Andreas Busch
Head of Global Drug Discovery, Bayer Schering Pharma
Big in Germany

Tracy Lefteroff
Tracy Lefteroff
Price Waterhouse Coopers
Looking to the future

Business Strategy

The ingredients for success are sometimes easily identifiable but they must deliver results. Innovative thinking, strategic advice, management strength and the ability to evolve and adjust are elements that companies seek from their executives as well as consulting partners. Making decisions is accounting for their consequences.

From corporate identity through to international trade and mergers, the challenges are often presented to consulting mavens that understand the nature of the pharmaceutical industry and the market fluctuations that present new opportunities and threats.

This knowledge translates to process changes in all departments of the organization, intersecting with developments in IT and marketing strategies, affecting operations and establishing standards along the enterprise, ultimately impacting business cycles, annual reports and the position in the marketplace.

Off with their overheads…
Or how one multinational pharmaceuticals manufacturer transformed its business process and dramatically reduced overhead through intelligent electronic information presentment.
More >>

Biotechnology in Ireland
Much has been written about the Irish success story: the Celtic Tiger, the Irish Miracle; the names and metaphors evolve as the country’s prosperity increases.
More >>

Final word
Indian generic pharmaceutical company Ranbaxy recently launched attacks around the globe on Pfizer’s patents for its anti-cholesterol drug, Lipitor. Lipitor is one of the world’s blockbuster drugs, with some putting the market in the region of US$12 billion annually.
More >>

Made to last
Ensuring the ongoing success of a Business Intelligence program.
More >>

The Publication COVER: Next Generation Pharmaceutical 12

See More >>

Sponsors

Vendor Perspectives

Article
The iuvo Microconduit Array (MCA)
BellBrook Labs
More >>

Article
The Top 3 Grid Application Areas for Pharma R&D: Drug Discovery, Clinical Analysis and Data Management
Univa UD
More >>

Article
4plex, real-time one-step RT-PCR without optimization
QIAGEN
More >>

Article
View from 37,000 feet – weathering change in the Pharmaceutical Industry
Triligent International
More >>

Article
Moving beyond rote case reporting: demonstrating a believable commitment to patient safety
ArisGlobal LLC
More >>

Article
Coping successfully with changing regulations in Experimental Clinical Pharmacology (Phase I)
Simbec Research Ltd
More >>

The Leader